Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-17. (Canceled).

18. (Currently amended) A compound having the Formula III:



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 is alkyl, haloalkyl, aminoalkyl, $C_{1\text{-}10}$ alkylaminoalkyl, di($C_{1\text{-}10}$)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

~~R_6 and R_7 are taken together to form a five or six membered carbocyclic or heterocyclic ring;~~

R_6 and R_7 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-OCH_2CH_2-$, or $-N(R_9)-CO-O-$; wherein R_9 is optionally substituted lower alkyl;

R_5 and R_8 are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido or thioalkoxy;

X is O or S; and

Y is optionally substituted aryl or optionally substituted heteroaryl.

19. (Cancelled)

20. (Currently amended) A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein:

Y is 

R_2 is H, alkyl, halo, amino, alkoxy, or nitro; and

R_3 and R_4 are taken together to form a five or six membered carbocyclic or heterocyclic ring.

21. (Currently amended) The compound according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R_3 and R_4 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-O-CH_2-CH_2-$, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

22. (Currently amended) A compound according to claim 18, wherein said compound is selected from the group consisting of:

2-[2-(Dimethylamino)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-Ethyl-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Imidazolyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

4-(3,4-Methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Piperidinyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2[2-(1-Pyrrolidinyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone, and

2-[2-(Ethoxycarbonyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone;

or a pharmaceutically acceptable salt thereof.

23. (Currently amended) A pharmaceutical composition comprising the compound of claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. (Currently amended) A method of treating, preventing or ameliorating neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia or surgery; or treating or ameliorating a neurodegenerative disease selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome; or treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids; or treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, migraine headache, glaucoma, retinitis, urinary incontinence or inducing anesthesia; or enhancing learning and cognition; or treating or ameliorating schizophrenia and myoclonus; comprising administering to an animal in need of such treatment an effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof.

25. (Original) The method of claim 24, wherein:

Y is 

R_2 is H, alkyl, halo, amino, alkoxy, or nitro; and

R_3 and R_4 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-O-CH_2-CH_2-$, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

26. (Original) The method according to claim 24, wherein said method is for treating, preventing or ameliorating global ischemia.

27. (Original) The method of claim 26, wherein said global ischemia is the result of cardiac arrest.

28. (Original) The method according to claim 24, wherein said method is for treating or ameliorating amyotrophic lateral sclerosis.

29. (Original) The method according to claim 24, wherein said method is for treating or ameliorating acute or chronic pain.

30. (Currently amended) A method of treating, preventing or ameliorating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof.

31. (Original) The method of claim 30, wherein:

Y is 

R_2 is H, alkyl, halo, amino, alkoxy, or nitro; and

R_3 and R_4 are taken together to $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-O-CH_2-CH_2-$, $-N=CH-O-$, $-NH-CO-O-$, $-CH=CH-CH=CH-$, or $-O-CH=CH-$.

32-34. (Canceled)

40. (New) The compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R_6 and R_7 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$ or $-O-CF_2-O-$.

41. (New) The compound according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R_3 and R_4 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$ or $-O-CF_2-O-$.

42. (New) The method of claim 25, wherein R_3 and R_4 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$ or $-O-CF_2-O-$.